Today: 10 June 2026
Browse Category

Pharmaceutical Industry 21 December 2025 - 27 December 2025

AbbVie Stock (ABBV) Holds Near $230 as Year-End “Santa Rally” Takes Shape; Dividend Boost, Legal Headlines and 2026 Outlook in Focus

AbbVie Stock (ABBV) Holds Near $230 as Year-End “Santa Rally” Takes Shape; Dividend Boost, Legal Headlines and 2026 Outlook in Focus

AbbVie closed Friday at $229.98, near its 52-week high, as U.S. markets ended a quiet post-holiday session with major indexes little changed. No major AbbVie corporate news broke in the past two days, but investor analysis and institutional filings kept the stock in focus. Institutions and hedge funds hold about 70% of shares. The next regular trading session is Monday.
27 December 2025
···
Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts

Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts

Pfizer shares closed Friday at $25.09, trading in a narrow range on light volume ahead of the New Year’s holiday. No new company press releases have appeared since Dec. 18. The stock remains below its 52-week high of $27.69, with dividend yield drawing investor focus as Wall Street weighs declining COVID revenues against future growth in oncology and obesity drugs.
27 December 2025
···
Wave Life Sciences (WVE) Stock Today: Obesity Drug Catalyst, $402.5M Financing, and What Investors Are Watching Next

Wave Life Sciences (WVE) Stock Today: Obesity Drug Catalyst, $402.5M Financing, and What Investors Are Watching Next

Wave Life Sciences shares fell 0.74% to $18.12 late Thursday morning, underperforming the broader market as biotech stocks slipped. Earlier this month, Wave reported positive Phase 1 data for its obesity drug candidate WVE-007 and raised $402.5 million in an upsized equity offering, extending its cash runway into Q3 2028.
26 December 2025
··
Eli Lilly (LLY) Stock After Hours Today (Dec. 25, 2025): Holiday Pause, GLP‑1 Catalysts, and What to Watch Before the Market Opens Dec. 26

Eli Lilly (LLY) Stock After Hours Today (Dec. 25, 2025): Holiday Pause, GLP‑1 Catalysts, and What to Watch Before the Market Opens Dec. 26

Eli Lilly shares closed at $1,076.98 after the early NYSE close on Dec. 24, with after-hours quotes near $1,077–$1,078 in thin holiday trading. U.S. exchanges remained shut Dec. 25 for Christmas. The 52-week range stands at $623.78 to $1,111.99. Trading volume is expected to rise when markets reopen Friday, with attention on GLP-1 policy and competition.
25 December 2025
·
Bristol-Myers Squibb (BMY) Stock News, Forecasts and Outlook as of Dec. 25, 2025: Breyanzi FDA Win, Eliquis Medicaid Deal, and 2026 Catalysts

Bristol-Myers Squibb (BMY) Stock News, Forecasts and Outlook as of Dec. 25, 2025: Breyanzi FDA Win, Eliquis Medicaid Deal, and 2026 Catalysts

Bristol-Myers Squibb closed at $54.71 on Dec. 24, 2025, after trading between $54.20 and $54.75, with a 52-week range of $42.52 to $63.33. The company agreed to provide Eliquis free to Medicaid starting in 2026 and will donate over seven tons of Eliquis API to the U.S. government. BMS also announced steep discounts for several drugs and secured three years of tariff relief.
25 December 2025
···
Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 24, 2025: Key News, Forecasts, and What to Watch Before the Next Market Open

Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 24, 2025: Key News, Forecasts, and What to Watch Before the Next Market Open

Bristol-Myers Squibb closed at $54.71 on Dec. 24, up 0.79%, with after-hours trading flat at $54.70 amid thin holiday volume. The NYSE session ended early for Christmas Eve. Analysts cited by MarketBeat maintained a “Hold” consensus and average 12-month target near current levels. No major company news moved the stock.
25 December 2025
··
Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open

Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open

Omeros shares jumped 75% to $15.36 in after-hours trading Wednesday after the FDA approved its first commercial product, YARTEMLEA, for a rare post-transplant complication. The stock saw heavy volume and a wide range, with multiple trading halts reported. U.S. markets closed early for Christmas Eve and will reopen Friday. The FDA had previously rejected the drug in 2021.
24 December 2025
··
Merck (MRK) Stock After Hours Today: Shares Hit a New 52-Week High on Dec. 24, 2025 — What to Know Before U.S. Markets Reopen

Merck (MRK) Stock After Hours Today: Shares Hit a New 52-Week High on Dec. 24, 2025 — What to Know Before U.S. Markets Reopen

Merck shares closed near $106.45 on Dec. 24, up 1.3%, hitting a new 52-week high in a shortened Christmas Eve session. The stock contributed to the Dow’s advance as U.S. markets posted record closes. Trading volume remained thin after hours. No new corporate news was released, but investors continued to react to last week’s drug-pricing agreement with the Trump administration.
24 December 2025
··
Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts

Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts

Edgewise Therapeutics shares jumped 21% to $26.37 intraday Wednesday after the company reported positive interim safety data for its EDG-7500 therapy in hypertrophic cardiomyopathy. The update showed no clinically meaningful LVEF reductions and no LVEF drops below 50% among 20 patients, with one new-onset atrial fibrillation event disclosed. Over 40 participants have enrolled in Part D of the trial.
24 December 2025
··
Merck (MRK) Stock After Hours Today (Dec. 23, 2025): Shares Slip Slightly After the Close as Investors Track TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Fresh Wall Street Targets

Merck (MRK) Stock After Hours Today (Dec. 23, 2025): Shares Slip Slightly After the Close as Investors Track TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Fresh Wall Street Targets

Merck closed Tuesday at $105.04, up 0.3%, then slipped to about $104.81 in after-hours trading. The stock is trading near its 52-week high of $105.84 after gains tied to new White House drug-pricing agreements and FDA fast-track headlines. Merck will sell several diabetes drugs at roughly 70% off list prices under the TrumpRx plan.
24 December 2025
··
Bristol-Myers Squibb (BMY) Stock News Today: Supreme Court Bid, Drug-Pricing Deals, Dividend Boost, and 2026 Forecasts (Dec. 23, 2025)

Bristol-Myers Squibb (BMY) Stock News Today: Supreme Court Bid, Drug-Pricing Deals, Dividend Boost, and 2026 Forecasts (Dec. 23, 2025)

Bristol-Myers Squibb shares traded near $54 midday Tuesday, down about 1%, after the company and Johnson & Johnson asked the U.S. Supreme Court to review challenges to Medicare drug price negotiations. Eliquis, a key Bristol Myers drug, is set for negotiated Medicare pricing starting January 1, 2026. Guggenheim reiterated a Buy rating on BMY despite new competition for its Camzyos therapy.
23 December 2025
··
Eli Lilly Stock (LLY) Today: Wegovy Pill Approval Raises the Stakes in GLP‑1s as Wall Street Forecasts Point to a High‑Expectation 2026

Eli Lilly Stock (LLY) Today: Wegovy Pill Approval Raises the Stakes in GLP‑1s as Wall Street Forecasts Point to a High‑Expectation 2026

Eli Lilly shares hovered near record highs Tuesday after the FDA approved Novo Nordisk’s first oral Wegovy pill, intensifying rivalry in the obesity drug market. LLY traded around $1,077 as investors weighed Novo’s launch against Lilly’s own oral candidate, orforglipron, which could reach the market in 2026. Both firms have signaled lower pricing for new pills as competition heats up.
23 December 2025
···
GSK Stock News Today (Dec. 23, 2025): Buyback Update, Director Buying, US Drug-Pricing Deal, and FDA Wins — What Analysts Forecast Next

GSK Stock News Today (Dec. 23, 2025): Buyback Update, Director Buying, US Drug-Pricing Deal, and FDA Wins — What Analysts Forecast Next

GSK disclosed a buyback of 232,912 shares on Dec. 19, 2025, at an average price of 1,807.58p, bringing total repurchases since late September to over 14.5 million shares. The company also reported director share purchases and reached a US drug pricing agreement. Shares traded near $48.59 Tuesday, little changed. Samsung Biologics agreed to buy a US facility from GSK for $280 million.
23 December 2025
·
Alnylam Pharmaceuticals (ALNY) Stock: Nasdaq-100 Entry, Amvuttra Momentum, Analyst Targets and Key Risks to Know Before the Dec. 22, 2025 Market Open

Alnylam Pharmaceuticals (ALNY) Stock: Nasdaq-100 Entry, Amvuttra Momentum, Analyst Targets and Key Risks to Know Before the Dec. 22, 2025 Market Open

Alnylam Pharmaceuticals joins the Nasdaq-100 before the U.S. market opens Dec. 22, prompting index-tracking funds to adjust positions. Shares last closed at $400.23. The company’s drug Amvuttra recently secured routine NHS use in England and Health Canada approval for ATTR cardiomyopathy. Alnylam also announced a $250 million manufacturing expansion and new FDA recognition for its technology platform.
22 December 2025
···
Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

BioMarin Pharmaceutical agreed Friday to acquire Amicus Therapeutics for $14.50 per share in cash, valuing the company at $4.8 billion. FOLD shares closed near $14.18 after jumping 30% on the news. The deal is expected to close in Q2 2026, pending shareholder and regulatory approvals. Amicus disclosed a $175 million breakup fee and a June 19, 2026 outside date.
22 December 2025
····
Amgen (AMGN) Stock Week Ahead Forecast: Drug-Price Deal Fallout, Analyst Targets, and Year-End Catalysts to Watch (Dec. 22–26, 2025)

Amgen (AMGN) Stock Week Ahead Forecast: Drug-Price Deal Fallout, Analyst Targets, and Year-End Catalysts to Watch (Dec. 22–26, 2025)

Amgen shares last traded near $327.38 as investors weighed a new FDA label expansion and U.S. drug-pricing deals announced Dec. 19. The NYSE will close early Dec. 24 and remain shut Dec. 25, thinning liquidity and increasing volatility risk. Amgen, a Dow component, remains sensitive to policy headlines and year-end positioning.
21 December 2025
···
Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

BioMarin Pharmaceutical will acquire Amicus Therapeutics for $14.50 per share in cash, valuing the deal at about $4.8 billion. Amicus stock closed at $14.18 on December 19, up 30% in a day and near the offer price. The deal is expected to close in Q2 2026, pending regulatory and shareholder approval. Amicus resolved key Galafold patent litigation ahead of the announcement.
21 December 2025
···
Pfizer Stock (PFE) in Focus: 2026 Guidance, Drug-Price Deal Pressures, and Pipeline Catalysts Investors Are Watching

Pfizer Stock (PFE) in Focus: 2026 Guidance, Drug-Price Deal Pressures, and Pipeline Catalysts Investors Are Watching

Pfizer forecast 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, both below Wall Street estimates. The company expects a $1.5 billion drop in COVID product sales and another $1.5 billion hit from patent expirations. Pfizer signed a Medicaid pricing deal with the Trump administration, warning of margin compression. Shares closed at $25.25 on Dec. 19.
21 December 2025
··
Vertex Pharmaceuticals (VRTX) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025: Casgevy Pediatric Data, Kidney Pipeline Momentum, and Journavx Launch Watch

Vertex Pharmaceuticals (VRTX) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025: Casgevy Pediatric Data, Kidney Pipeline Momentum, and Journavx Launch Watch

Vertex Pharmaceuticals reported new pediatric results for Casgevy on Dec. 6, showing all four children with severe sickle cell disease were free of vaso-occlusive crises for at least 12 months. Twelve pediatric beta thalassemia patients remained transfusion-free for at least a year. Vertex plans global regulatory filings in 2026. One TDT patient died from busulfan-related complications.
21 December 2025
··
1 … 3 4 5 6 7 … 9

Stock Market Today

  • Palantir Technologies (PLTR) Shares Seen Fairly Valued Amid Recent Decline
    June 10, 2026, 5:48 PM EDT. Palantir Technologies has seen its share price fall 13.2% over the past week and 21.3% year to date, following extraordinary gains in prior years. At $132.07 per share, Palantir trades slightly below its estimated intrinsic value of $145.11 based on a Discounted Cash Flow (DCF) analysis, suggesting a modest 9% discount. The company posted $2.69 billion in free cash flow over the past twelve months, with projections rising to $16.11 billion by 2030. Despite recent volatility tied to sentiment on artificial intelligence and software spending, Palantir remains fairly valued but not a clear bargain. Investors should monitor further market developments and valuation metrics to gauge future opportunities or risks.

Latest articles

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

10 June 2026
Parabilis Medicines soared 58% above its $20 IPO price to close at $31.60 in its Nasdaq debut after raising a record $670 million, reflecting strong investor demand for its Helicon drug platform ahead of a pivotal Phase 3 desmoid tumor trial planned for 2027; Regeneron’s $75 million private placement added credibility.
Joby Aviation Shares Slip After CFO Files to Sell Stock

Joby Aviation Shares Slip After CFO Files to Sell Stock

10 June 2026
Joby Aviation fell 4.47% to $8.86 after CFO Rodrigo Brumana disclosed selling 78,489 shares under a prearranged 10b5-1 plan, with no new certification or commercial-launch updates, leaving investors focused on regulatory progress and cash burn as the key catalysts for the stock.
YY Group Shares Spike as Humanoid Robot Plans Unveiled

YY Group Shares Spike as Humanoid Robot Plans Unveiled

10 June 2026
YY Group Holding shares surged to $0.165 on heavy volume after announcing a commercial humanoid-robotics initiative using Unitree G1 robots and facility-management data, reframing the company as a robotics-and-AI data play; the rally comes despite 2025 net loss, dilution risk from a relaunched at-the-market share-sale program, and no disclosed robot-related revenue or contracts.
Go toTop